** Shares of precision oncology firm Black Diamond Therapeutics BDTX.O rise 35.1% to $2.26 premarket
** BDTX and French drugmaker Servier say they have entered into a licensing agreement for BDTX-4933, a small molecule designed by Black Diamond
** BDTX will receive an upfront payment of $70 million and will be eligible to receive up to $710 million in development and commercial sales milestone payments, along with tiered royalties based on global net sales
** Under the agreement, Servier will develop and commercialize BDTX-4933 for solid tumors including non-small cell lung cancer
** BDTX-4933 is currently in early-stage development
** Up to last close, BDTX has fallen 64.2% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.